Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,650 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stage III substaging and outcomes in patients with bladder cancer undergoing radical cystectomy.
Hara S, Fukuokaya W, Miki J, Taoka R, Saito R, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Kimura T; Japan Urological Oncology Group. Hara S, et al. Among authors: yamamoto s. Int J Urol. 2025 Feb 5. doi: 10.1111/iju.70005. Online ahead of print. Int J Urol. 2025. PMID: 39907200
Multimodal mechanisms of human centriole engagement and disengagement.
Ito KK, Takumi K, Matsuhashi K, Sakamoto H, Nagai K, Fukuyama M, Yamamoto S, Chinen T, Hata S, Kitagawa D. Ito KK, et al. Among authors: yamamoto s. EMBO J. 2025 Feb 4. doi: 10.1038/s44318-024-00350-8. Online ahead of print. EMBO J. 2025. PMID: 39905228
Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC.
Tohi Y, Kobayashi K, Daizumoto K, Sekino Y, Fukuhara H, Niigawa H, Katayama S, Shimizu R, Takamoto A, Nishimura K, Nagami T, Hayashida Y, Hirama H, Shiraishi K, Tomida R, Kobatake K, Inoue K, Miyaji Y, Bekku K, Morizane S, Miura N, Wada K, Sugimoto M; Chu-shikoku Japan Urological Consortium. Tohi Y, et al. Jpn J Clin Oncol. 2025 Feb 2:hyaf025. doi: 10.1093/jjco/hyaf025. Online ahead of print. Jpn J Clin Oncol. 2025. PMID: 39893578
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium.
Uchimoto T, Iwatsuki K, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Minami T, Yamamoto Y, Yamazaki S, Takai T, Sakamoto M, Nakajima Y, Nishimura K, Maenosono R, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yoshikawa Y, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Fujita K, Kimura T, Ohno Y, Shiroki R, Azuma H. Uchimoto T, et al. Among authors: yamamoto s. Int J Clin Oncol. 2025 Jan 31. doi: 10.1007/s10147-025-02709-1. Online ahead of print. Int J Clin Oncol. 2025. PMID: 39890750
10,650 results
You have reached the last available page of results. Please see the User Guide for more information.